Selection of appropriate endpoints for rare disease clinical studies can be challenging but is critical to assessing the efficacy of new medicines. Engaging with patient communities to determine endpoints ensures appropriate measurements of success for all stakeholders and de-risks recruitment and retention strategies. Post-approval, appropriately set clinical research endpoints result in meaningful treatment assessment and delivery by clinicians and patients.
In this white paper, you’ll learn:
- How to determine valid clinical research endpoints
- How to engage with patient advocacy organizations to support product development
- How to select endpoints relevant to all stakeholders including patients, caregivers, and practitioners
Explore related content and topics
Page
Healthcare Intelligence: Q&A with Amy Raymond
Amy Raymond is anything but ordinary. Her passion for marine science, experiences in research, and perspectives make her particularly unique. In this…
Blog
The Fight Against ALS
Therapeutic Experts Bill Holt, DO (Executive Director, Neurosciences) and Amy Raymond, PhD (Clinical Scientist, Rare Diseases) will be attending the…
Newsletter
Rare Diseases Newsletter
This quarterly publication strives to keep you up to date on PRA’s Center for Rare Diseases initiatives and activities. Interested in learning more…